BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-212@pharmaconomics
DTSTAMP:20260707T034519Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:VNDA Phase 3 — Bysanti (estimated date)
DESCRIPTION:Phase 3 trial results for Bysanti in major depressive disorder (MDD) are due ~ Mar 31\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda8-k562026exhibit991.htm\n\nTrack it: https://www.pharmaconomics.com/e/212
URL:https://www.pharmaconomics.com/e/212
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VNDA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR